Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29820003 | 1.00 | CYP19A1 (0.70) | CYP19A1ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL28263864 | 0.87 | CYP19A1 (0.68) | CYP19A1CCR1CCR2 | |
| SCHEMBL12468753 | 0.80 | CYP19A1 (0.55) | CYP19A1ALDH1A1POLBKDM4ECCR1 | |
| SCHEMBL6712996 | 0.79 | CYP19A1 (0.58) | CYP19A1CCR1CCR2 | |
| SCHEMBL305310 | 0.79 | CYP19A1 (0.58) | CYP19A1CCR1CCR2CYP2A13 | |
| SCHEMBL11128645 | 0.79 | CYP19A1 (0.70) | CYP19A1KMT2AMEN1L3MBTL1CYP3A4 | |
| SCHEMBL8801557 | 0.79 | CYP19A1 (0.58) | CYP19A1ALDH1A1KMT2AMEN1CCR1 | |
| SCHEMBL1281769 | 0.79 | CYP19A1 (0.58) | CYP19A1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL9125316 | 0.79 | CYP19A1 (0.58) | CYP19A1KMT2AMEN1CCR1CCR2 | |
| SCHEMBL31286288 | 0.78 | CYP19A1 (0.53) | CYP19A1ALDH1A1KMT2APOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025574-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12116354-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230112865-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2023-04-13 | — | — | US | disclosed |
| US-20230113841-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11407736-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-4025574-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114728918-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3788044-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210009537-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210002237-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20200407332-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-10815206-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190337907-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| US-8969556-B2 | Purine-based triazoles | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045866-A1 | PURINE-BASED TRIAZOLES | CASE WESTERN RESERVE UNIVERSITY | 2014-02-13 | — | — | US | disclosed |
| WO-2012051296-A2 | PURINE-BASED TRIAZOLES | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-20210009537-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-20230112865-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-11407736-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-20200407332-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-20210002237-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-12116354-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-20140045866-A1 | PURINE-BASED TRIAZOLES | PNP, TK2, NME4 | CYP19A1 4083/4885ALDH1A1 3400/4885KMT2A 3379/4885 |
| US-20230113841-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-20190337907-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
| US-10815206-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | CYP19A1 4673/4885ALDH1A1 4505/4885KMT2A 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.